학술논문

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Document Type
Article
Source
In: Therapeutic Advances in Medical Oncology. (Therapeutic Advances in Medical Oncology, 2022, 14)
Subject
Language
English
ISSN
17588359
17588340